Canaccord Genuity analysts downgraded Intra-Cellular Therapies (NASDAQ:ITCI) stock from Buy to Hold, adjusting the price target to $132 from the previous $119. The revision follows the recent ...

Read here for an update on Yacktman Asset Management's portfolio changes, top holdings, and performance compared to market ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...